Purpose of Review Due to advancements in oncologic treatment strategies and techniques, the number of survivors who have undergone hematopoetic stem cell transplant (HCT) continues to increase in the United States; this number is projected to reach 502,000 by the year 2030. There is significant interest within the field of cardio-oncology to identify cardiotoxicity and cardiovascular disease in the HCT population. Epidemiologic studies analyzing both short-and long-term cardiovascular effects, risk stratification modeling, cardioprotective strategies, and expert consensus documents for cardiotoxicity surveillance recommendations are reviewed. Recent Findings Patients who have undergone HCT are at increased risk of cardiovascular events and mortality compared to matched controls. The type of cardiotoxicity and the incidence rates vary based on specific therapeutic regimens and pre-existing cardiovascular risk factors. Life-threatening cardiotoxicity can present during HCT as acute heart failure, arrhythmias, pericardial tamponade, or cardiac arrest; or it can present late after treatment as cardiomyopathy, ischemic heart disease, vascular disease, stroke, or comorbid conditions, such as hypertension and diabetes mellitus that are associated with cardiac events. Summary HCT is associated with excess cardiovascular risk partially due to exposure to cardiotoxic chemotherapy and radiation, as well as indirect and direct detrimental effects on cardiovascular reserve. This review discusses the epidemiology and the known cardiotoxic effects of historical chemoradiation agents in addition to newer targeted therapies. Recent expert consensus statements from cardiology and hematology/oncology societies are reviewed in regard to risk stratification of the cancer patient based on the type of treatments. Finally, gaps in knowledge are identified with proposed avenues of research that will allow for more accurate risk assessment, prediction, and potential treatment of the HCT patient in attenuating the risk of developing both short-and long-term cardiovascular comorbidities.
Introduction
Hematopoietic stem cell transplant (HCT), also referred to as bone marrow transplant (BMT), is an important therapeutic option for certain hematologic and lymphoproliferative conditions in which long-term survival is the goal. The transplant involves initial ablation of the marrow and, then, reconstitution of hematopoiesis with either genetically identical marrow This article is part of the Topical Collection on Cardio-oncology (such as patient's own or identical twin, also called autologous and syngeneic, respectively) or histocompatible marrow (such as from an allogeneic donor) [1] . The population of HCT survivors is expected to increase significantly by 2030. Currently, there are an estimated 108,900 transplant survivors in the US, including both allogeneic and autologous transplant recepients [2] . This number is expected to increase to 502,000 survivors by 2030 in the US based on data from the Center for International Blood and Marrow Transplant Registry (CIBMTR) [2] .
Preparative regimens are an essential part of transplant because they provide immunosuppression to allow engraftment and help eradicate the underlying neoplastic disease. Preparative strategies consist of fully myeloablative, reduced intensity, or non-myeloablative conditioning regimens containing several combinations of chemotherapeutic regimens and/or radiation, some of which have known cardiotoxic effects. Different protocols are used depending on the recipient's comorbidities, risk of rejection, and the underlying disease, and they often include some combination of total body irradiation (TBI), busulfan, cytarabine, fludarabine, cyclophosphamide, idarubicin, thiotepa, and/or melphalan [3] . For allogeneic transplants, methotrexate and cyclosporine are used for prevention of graft versus host disease (GVHD). If GVHD does occur, corticosteroids are an important aspect of immunosuppressive therapy and are often required for extended periods of time. Acute and/or chronic GVHD can be treated with various immunosuppressive medications that may also have cardiotoxic effects.
A practitioner should be aware of chemotherapy and radiation exposure administered during prior treatments; these treatments will vary widely depending on each patient's diagnosis but can constitute significant risk factors for developing toxicity during and following HCT. One example includes anthracyclines that are commonly used for the treatment of hematologic malignancies and are known to cause significant cardiotoxicity that can manifest as ventricular dysfunction and HF.
Multiple studies have shown that HCT survivors have poorer long-term survival than expected due to multiple factors, including relapsed disease, infection, graft versus host disease, and cardiac events [4] . The literature on the incidence of cardiac events in patients who have undergone HCT, the treatment-related and patient-specific factors that impact risk of cardiotoxicity, as well as the current guidelines for cardiotoxicity surveillance both during and following HCT in cancer patients are reviewed.
Incidence of Cardiotoxicity During Hematopoietic Stem Cell Transplant
Studies have shown that the overall incidence of cardiotoxicity during HCT is moderate (range 0.9-8.9% depending on the study [5] [6] [7] [8] ) and includes serious and potentially fatal complications, such as congestive heart failure (CHF), arterial events, tamponade, and rhythm disturbances. There are often significant differences in the definition of cardiotoxicity between studies resulting in a wide range of reported cardiotoxicity rates. Several single-center studies [5] [6] [7] [8] have evaluated the spectrum of cardiotoxicity across institutions and various preparative regimens in patients undergoing HCT.
A retrospective study of 2821 patients undergoing BMT at the University of Minnesota from 1977 to 1997 reported an incidence of major or fatal cardiotoxicity of 0.9%. Cardiotoxicity was defined as development of heart failure (HF), pericardial tamponade, ventricular fibrillation cardiac arrest, and cardiac arrhythmias [5] . In a single-center study of 170 BMT patients at the University of Ulm in Germany, incidence of cardiotoxicity was 4.7% overall and 1.8% for life-threatening cardiotoxicity, defined as pericardial effusion, HF, or sudden cardiac arrest [6] . The authors found that a reduction in left ventricular ejection fraction (LVEF) before transplant was a risk factor for minor cardiac events; however, it was not predictive of life-threatening cardiotoxicity [6] . Similarly, Fujimaki et al. reported that 3 of 80 (3.8%) HCT patients treated at the Kanagawa Cancer Center in Japan from 1994 to 1999 with a preparative regimen of thiotepa, cyclophosphamide, and TBI suffered severe cardiac toxicity. Severe cardiotoxicity was defined as grade III or IV cardiotoxicity with CHF, and all 3 patients subsequently died. Pre-existing reduction in LVEF, cumulative dose of anthracycline, and multiple chemotherapy regimens correlated with cardiac complications [8] . Kupari et al. specifically evaluated the incidence of CHF in 45 BMT patients one month after receiving cyclophosphamide and TBI and found that 4/45 (8.9%) patients were affected [7] .
Among the more common cardiac complications seen during transplant are arrhythmias. One retrospective study reviewed 1177 adult patients receiving HCT over a ten-year period at the Memorial Sloan-Kettering Cancer Center and showed an incidence of 5.2% (61/1177) for developing an arrhythmia during or following transplant [9] . The most frequently encountered arrhythmias included atrial fibrillation, atrial flutter, and supraventricular tachycardia [9] . In this study, the authors found that developing post-transplant arrhythmias was predictive of longer hospitalization, increased likelihood of needing intensive care, and an increased risk of death (OR 3.5) at 1 year post-transplant [9] .
Incidence of Late Cardiotoxicity in Hematopoietic Stem Cell Transplant Survivors
Late cardiotoxicity many years following HCT is well-described and appears to be more common than early cardiotoxicity. In a single-center retrospective cohort study of 1491 patients, patients [10] .
Armenian et al. evaluated the incidence of CHF in patients at least one year post-HCT treated at the City of Hope National Medical Center in a case-control study. The authors found that the incidence of CHF was 11.7% with a median time of CHF onset of 3 years post-transplant [11] . Armenian et al. subsequently reported that the incidence of CHF among 1244 autologous HCT survivors treated at the City of Hope between 1988 and 2002 was 4.8% at 5 years and 9.1% at 15 years following transplant. Female lymphoma survivors had among the highest rate (14.5% at 15 years) of CHF, which may be due to the increased susceptibility to anthracyclinerelated cardiotoxicity in women compared to men [12] . Prior anthracycline therapy (OR 9.9) and other comorbidities (HTN + anthracycline OR 35.3; DM + anthracycline OR 26.8) significantly increased the risk of CHF [12] .
Cardioprotective medications, such as angiotensinconverting enzyme inhibitors (Ace-I) and beta-blockers, may decrease the risk of LVEF reduction and HF; however, there is an overall lack of randomized clinical trials in the HCT population. Ninety patients with acute leukemia or hematologic malignancies undergoing autologous HCT were treated with either enalapril and carvedilol or control in a randomized controlled trial (OVERCOME) by Bosch et al. Compared to patients who did not receive either Ace-I or beta-blockers, patients treated with enalapril and carvedilol were less likely to suffer from a combined endpoint of death/HF/final LVEF < 45% (6.7% vs. 24.4%) [13••] .
In addition to CHF, post-HCT patients are at risk of arterial events, such as coronary artery disease (CAD), cerebrovascular accidents (CVA or stroke), and peripheral artery disease (PAD). Compared to autologous HCT, allogeneic HCT survivors are more likely to experience cardiovascular events, including stroke, coronary artery disease, and peripheral artery disease (RR 6.92) [14] . In patients who have received an allogeneic HCT, the risk of arterial events, including CAD and CVA, is 10% at 15 years and > 20% at 20 years [14, 15] . A retrospective multicenter study of BMT survivors from the European Group of Blood and Marrow Transplantation reported a 3.6% incidence of cardiovascular events, including CAD and PAD, at a median age of 54 years (range 41-70 years) [16] .
Cardiotoxicity has been identified as a significant cause of mortality in the HCT patient population as well. In 854 autologous HCT survivors who were registered in the Bone Marrow Transplant Survivor Study (BMTSS), cardiac events accounted for 2.4% of late death (≥ 2 years after transplant) [17] . In allogeneic HCT survivors, late cardiac deaths accounted for 3% of mortality [18] .
Factors Impacting Incidence of Cardiotoxicity
Many factors influence the development of cardiotoxicity in patients undergoing HCT. First, any prior cardiotoxic treatments, such as anthracyclines and chest radiation, increase the risk of subsequent cardiotoxicity. In addition, development of comorbid conditions, such as HTN, DM, or HLD from HCT-related therapies or GVHD, is associated with subsequent long-term risk of CV disease. Many agents that are used prior to transplant for the treatment of the underlying primary hematologic malignancy, during HCT conditioning, and post-HCT for maintenance, have the potential to cause short-and long-term cardiotoxicity (Table 1) . Chemoradiation therapy strategies and the evidence for their use in these malignancies are beyond the scope of this review.
Anthracyclines
Although anthracyclines are not typically used as part of the preparative regimen, they are commonly used to treat hematologic malignancies. The majority of patients with acute leukemia eligible for transplant will have received anthracyclines as part of the induction and/or consolidation portion of therapy. Those patients who have received anthracyclines prior to HCT are at significantly increased risk of cardiovascular death [69] . The cumulative anthracycline dose is predictive of cardiac complications post-transplant [70, 71] . In a nested case-control design of HCT survivors treated at City of Hope, receiving an anthracycline dose of ≥ 250 mg/m 2 was associated with late-onset CHF (OR 3.2) [11] . CPX-351, a liposomal formulation of daunorubicin and cytarabine, has shown a significant overall survival benefit compared to standard cytarabine and daunorubicin (7 + 3) chemotherapy in acute myeloid leukemia [47] , allowing a once poor-risk group of AML patients to proceed to HCT. The longterm cardiac toxicities with the liposomal formulation of the anthracycline in CPX-351 with or without HCT have yet to be delineated.
Chest Radiation
Chest radiation is a well-known cause of cardiovascular morbidity and mortality [72] . For example, a study of Hodgkin's lymphoma survivors with prior radiation therapy (48% of whom received ≥ 30 Gy) showed that coronary artery disease was present in 12 of 31 (39%) patients based on coronary CT angiography [73] . In HCT survivors, chest radiation prior to transplant is associated with a 9.5-fold increase in CAD [74] .
Cyclophosphamide
Cyclophosphamide is an alkylating agent commonly used in HCT preparative regimens to ablate the bone marrow. Cyclophosphamide is well-known to cause cardiotoxicity especially at higher doses > 100 mg/kg. Potential toxicity includes severe myocarditis, exudative pericarditis, myocardial depression, malignant arrhythmia, and CHF [75] . In a study of BMT patients from Brigham and Women's Hospital who were receiving either once daily lower-dose cyclophosphamide (mean total 87 ± mg/kg) or twice daily higher-dose of cyclophosphamide (mean total 174 ± 34 mg/kg), cardiotoxicity was noted in 5 of 44 (11%) patients [76] . The majority of patients who experienced cardiotoxicity received the higher-dose of cyclophosphamide. Cardiotoxicity included dyspnea/edema, chest pain, pericardial effusion, and atrial arrhythmia (flutter or fibrillation). Three of the five patients had received anthracyclines previously (range 250-720 mg/m 2
). An LVEF < 50% prior to transplant was predictive of cardiotoxicity [76] .
Graft Versus Host Disease
GVHD is a condition where immune cells from the donor's marrow attack healthy tissue of the recipient by recognizing those cells as being "non-self." GVHD is a common complication of allogeneic HCT where bone marrow or stem cells are taken from a non-genetically identical donor; however, it is not seen with autologous HCT. Development of GVHD may be one factor explaining the higher rate of cardiotoxicity observed in patients undergoing allogeneic HCT compared to autologous HCT [15] . There are several explanations for why GVHD may predispose patients to cardiovascular events. First, a history of grade II-IV acute GVHD is associated with development of established cardiovascular risk factors, such as DM (RR 5.8), HTN (RR 9.1), and HLD (RR 3.2) [69] . Development of these comorbidities is likely related to side effects of steroids and calcineurin inhibitors which are commonly used for the treatment of GVHD [69] . Additionally, ibrutinib, which was recently approved for the treatment of chronic GVHD, is associated with atrial fibrillation [40] . Ruxolitinib, in the off-label treatment of steroid-refractory GVHD, has also been added to the GVHD treatment armamentarium with known increased incidence of hyperlipidemia [77] . Lastly, GVHD may also affect the vascular endothelium itself, causing injury and inflammation that can predispose to arterial events [78] . If it affects serosal tissue, it can present similarly to autoimmune diseases, such as systemic lupus erythematosus, with development of pericardial effusion or tamponade [79] .
Comorbidities/Cardiovascular Risk Factors
HCT survivors have increased risk of developing medical comorbidities. TBI which is typically done as part of the preparative regimen is associated with an increased risk of DM (OR 3.4) [80] and HLD [69] . 
Surveillance Guideline Recommendations
Major recommendations for the management of cancer patients receiving cardiotoxic treatment from five different groups are reviewed ( 
American Society of Echocardiography/European Association of Cardiovascular Imaging
The American Society of Echocardiography (ASE) and the European Association of Cardiovascular Imaging (EACVI) released a joint expert consensus statement in 2014 proposing cardiotoxicity imaging surveillance algorithms based on the chemotherapy regimen. While these guidelines do not specifically address HCT survivors, they do provide surveillance guidelines for anthracycline agents that are commonly used for the treatment of many hematologic malignancies. Anthracyclines are considered "type I" agents which refer to chemotherapeutic agents known to cause irreversible cardiac injury due to cardiomyocyte necrosis, although this classification is oversimplified and not likely accurately reflective of the complex mechanisms contributing to cardiotoxicity with various chemotherapeutic agents [82••] . Patients who receive anthracyclines should have an assessment of cardiac function, including LVEF prior to anthracycline initiation, at the end of treatment, and again 6 months after completion of therapy (do you have a reference for this?) [82••] . Echocardiography is the preferred first-line imaging modality for assessment of cardiac function and structure. For anthracycline doses > 240 mg/m 2 , an echocardiogram for ventricular function should be repeated prior to each additional dose of 50 mg/m 2 . Cardiac assessment with 3D echocardiography is preferable; however, if 2D echocardiography is used, then additional evaluation with contrast for more precise endocardial enhancement, and global longitudinal strain (GLS) and checking serial troponin level should be considered. Cardiology consultation is appropriate for patients with abnormal LVEF (< 53%), abnormal GLS, or positive troponin level [82••] .
The ASE/EACVI released separate guidelines for patients with prior radiation therapy in 2013 [83•] . Patients with prior radiation exposure are at risk for multiple cardiac complications, including coronary artery disease, restrictive cardiomyopathy, valvular dysfunction, and constrictive pericarditis. Given the potential for numerous complications, patients exposed to radiation therapy should have an annual clinical assessment with a thorough evaluation of cardiovascular system symptoms. For asymptomatic patients, a screening echocardiogram is recommended 5 or 10 years following treatment depending on risk factors. Patients with history of anterior or left sided chest radiation with any one of the following are considered high risk: > 30 Gy of radiation, < 50 years at time of exposure, > 2 Gy/day of radiation, lack of shielding, tumor in or next to the heart, receiving concomitant chemotherapy with known high risk of cardiotoxicity, pre-existing cardiovascular disease, or multiple cardiovascular risk factors. Evaluation for coronary artery disease with a functional non-invasive stress test should also be considered for high risk patients 5-10 years post-exposure [83• ].
Children's Oncology Group Long-Term Follow-Up
The Children's Oncology Group (COG) Long-Term Followup guidelines provide surveillance recommendations for organ toxicity for patients who are ≥ 2 years post-transplant based on their exposure history. They emphasize pretransplant treatments, such as anthracycline and radiation therapy, which both heavily impact cardiac toxicity risk. Patients with a history of anthracycline/anthraquinone chemotherapy or chest radiation should have an annual history and physical with a thorough assessment of cardiac symptoms. Aggressive cardiovascular risk factor treatment is recommended for all bone marrow transplant survivors. Assessment of cardiac function should be done every 1-5 years depending on the individual's exposure type, cumulative dose, and age at time of exposure. Patients who have received cranial radiation should also be screened for development of neurologic symptoms which may be a sign of cerebrovascular disease [84, 
Future Avenues and Strategies
Preventive and therapeutic strategies for cardiovascular complications in the HCT population are poorly studied. To our knowledge, there has only been one randomized controlled trial (OVERCOME trial) evaluating the benefit of cardioprotective strategies in patients undergoing HCT; however, this study only looked at autologous HCT patients with short-term follow-up of 6 months. The authors reported that Ace-I and beta-blockers might prevent against LVEF reduction in patients with hematologic malignancies receiving intensive chemotherapy. Given these results, initiation of cardioprotective medications may also be helpful to patients undergoing allogeneic transplant who have an even higher incidence of cardiovascular events overall; however, this needs to be studied further.
Cancer patients often suffer from generalized fatigue and have reduction in their exercise capacity during and after treatment [88•] . HCT survivors have low peak oxygen uptake, a measure of cardiopulmonary fitness, which are on average 22% less than age-and sex-predicted values [89] . A singlecenter study of allogeneic BMT patients showed that an 8-week outpatient and home-based exercise and education program instituted after transplant can improve exercise capacity and quality of life [90] . Similarly, a study of children undergoing HCT transplant showed that supervised exercise during HCT can improve functional performance, mobility, and strength [91] . There is now increasing interest in implementing exercise programs prior to transplant (termed prehabilitation) in order to potentially prevent transplantrelated cardiovascular complications based in part on encouraging results from animal studies which show that exercise can reduce anthracycline-related cardiotoxicity [88•] . Randomized research studies are needed to understand the possible benefit of exercise in functional capacity, quality of life, as well as cardiovascular outcomes. Multiple on-going studies will hopefully provide many answers regarding the safety and benefit of exercise including the following: the Feasibility of Pre Transplant Exercise (pre-habilitation) for Multiple Myeloma Patients Awaiting Autologous Stem Cell Transplantation (PREeMPT) study [92] , the EXercise to prevent AnthrCycline-based Cardio-Toxicity (EXACT) in individuals with breast or hematological cancers' study [93] , and the rationale and design of the multidisciplinary team IntervenTion in cArdio-oNcology study (TITAN) [94] .
While there are screening recommendations for patients with exposure to anthracyclines or radiation, guidelines targeted to HCT patients who receive a wide spectrum of cardiotoxic medications are lacking and mainly provide recommendations for management during survivorship. Defining high-risk patients prior to transplant who may benefit from early cardiology evaluation, pre-transplant ischemia evaluation, initiation of cardioprotective agents, and/or closer monitoring during treatment is critical to ensuring optimal care for cancer patients. For example, initiation of statin therapy for patients with elevated calcium scores on chest CT scans, which are routinely done as part of cancer staging, can be c o n s i d e r e d f o r p r e v e n t i o n o f c o r o n a r y e v e n t s . Pharmacogenetic testing for susceptibility to anthracyclineinduced cardiotoxicity that is already recommended in children with cancer can also be studied in adult cancer patients in an effort to identify those who are most vulnerable [95] . While the agent dexrazoxane has been studied in the pediatric and advanced breast cancer population with demonstrated cardioprotective effects [96, 97] , its use and efficacy in the adult hematologic population is less clear. It may be of interest to study the use of dexrazoxane in adult patients with significant cardiac risk factors and/or preexisting cardiomyopathy entering transplantation who would benefit from anthracycline treatments for their hematologic condition. The goal going forward should be to focus on both prevention as well as surveillance and treatment.
Cancer and cardiovascular disease share overlapping risk factors, including behaviors, such as tobacco use and sedentary lifestyle, comorbidities, such as hypertension and diabetes, and processes, such as infection and inflammation [98] . The recent CANTOS trial, which investigated an antiinflammatory monoclonal antibody-canakinumab-which targets interleukin-1β, demonstrated both a reduction in cardiovascular events and a reduction in lung cancer-related mortality; these preliminary findings suggest that inflammation is a potentially significant contributor to development of both cardiac and oncologic disease states [99] . Understanding and identifying mechanistic overlap in pathogenesis opens the door to smarter drug development for both conditions and can improve the ability to both anticipate and treat cardiotoxicity. Non-clinical models of cardiomyocytes, including in vivo, in vitro, and in silico models, are essential for pushing our understanding of the mechanism of cardiotoxicity across various agents at the basic level. They also offer an opportunity for advancing personalized medicine for cancer patients through the use of patient-derived somatic cells [100] .
Recent efforts to uncover genetic causes of hematologic malignancies have revealed an unexpected link to atherosclerotic disease. An age-related disorder defined by an expansion of hematopoietic clones with recurrent somatic mutations (particularly loss-of-function alleles in the genes DNMT3A, TET2, and A SXL1 t hat are mutations found in myelodysplastic syndrome and acute myeloid leukemia) was more common in older people and was defined as clonal hematopoiesis of indeterminate potential (CHIP) without having any active underlying malignancy [101] . An exploratory analysis revealed that people with CHIP had an increased risk of hematologic cancers as well as an increased risk of death from any cause [102] ; subsequent case-control analyses revealed that the incidence of coronary heart disease and myocardial infarction was 1.9 and 4.0 times greater than in non-carriers, respectively. CHIP carriers with the above-mentioned mutations along with JAK2 also had increased coronary artery calcification [103•] . These overlapping links provide the grounds to potentially investigate if patients who develop hematologic malignancies with these mutations may be prone to cardiotoxicity or cardiovascular events with treatment in the short-and long-term.
The transition from active cancer treatment to long-term survivorship is a vulnerable time for the increasing number of cancer survivors. While there has been progress in patient education regarding the potential long-term cardiotoxic effects of cancer treatments, more awareness and education for physicians is also essential. Many cancer survivors return to the care of general medicine providers for whom it is nearly impossible to keep up with the increasing quantity of treatments and all of their potential complications. The rise of the cardio-oncologist, who focuses on the specific cardiac needs of cancer patients, is one step that can hopefully improve longterm care of cancer patients. Cardio-oncologists can also serve as a valuable partner in recognizing and reporting complications from new therapies as they arise alongside oncologists. In addition, creating large nationwide registries to track cardiovascular complications is essential especially in light of an ever-growing number of novel targeted oncologic therapies in use with uncertain real-life cardiotoxicity profiles.
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